Indication
Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.
Loading your page…
Loading your page…
Influenza, Human
Marketing Authorisation Holder: Biocryst
EMA Authorisation: 13/04/2018
INN: peramivir
AI Drug & Interaction Analysis
Free account required
Ask Osler about Alpivab: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.